FibroGen, Inc. (FGEN)

FibroGen Statistics

Total Valuation

FibroGen has a market cap or net worth of $71.13 million. The enterprise value is $33.11 million.

Market Cap	71.13M
Enterprise Value	33.11M

Important Dates

The next estimated earnings date is Tuesday, March 4, 2025, after market close.

Earnings Date	Mar 4, 2025
Ex-Dividend Date	n/a

Share Statistics

FibroGen has 100.77 million shares outstanding. The number of shares has increased by 3.41% in one year.

Current Share Class	100.77M
Shares Outstanding	100.77M
Shares Change (YoY)	+3.41%
Shares Change (QoQ)	+0.68%
Owned by Insiders (%)	1.05%
Owned by Institutions (%)	32.10%
Float	92.91M

Valuation Ratios

PE Ratio	n/a
Forward PE	n/a
PS Ratio	0.39
Forward PS	0.52
PB Ratio	-0.35
P/TBV Ratio	n/a
P/FCF Ratio	n/a
P/OCF Ratio	n/a
PEG Ratio	n/a

Enterprise Valuation

EV / Earnings	n/a
EV / Sales	0.18
EV / EBITDA	n/a
EV / EBIT	n/a
EV / FCF	n/a

Financial Position

The company has a current ratio of 1.28

Current Ratio	1.28
Quick Ratio	0.98
Debt / Equity	n/a
Debt / EBITDA	n/a
Debt / FCF	n/a
Interest Coverage	-6.00

Financial Efficiency

Return on Equity (ROE)	n/a
Return on Assets (ROA)	-20.53%
Return on Invested Capital (ROIC)	n/a
Return on Capital Employed (ROCE)	-161.10%
Revenue Per Employee	$370,401
Profits Per Employee	-$250,603
Employee Count	486
Asset Turnover	0.50
Inventory Turnover	6.04

Taxes

Income Tax	-137,000
Effective Tax Rate	n/a

Stock Price Statistics

The stock price has decreased by -60.78% in the last 52 weeks. The beta is 0.75, so FibroGen's price volatility has been lower than the market average.

Beta (5Y)	0.75
52-Week Price Change	-60.78%
50-Day Moving Average	0.51
200-Day Moving Average	0.63
Relative Strength Index (RSI)	65.93
Average Volume (20 Days)	7,174,587

Short Selling Information

The latest short interest is 2.91 million, so 2.88% of the outstanding shares have been sold short.

Short Interest	2.91M
Short Previous Month	3.07M
Short % of Shares Out	2.88%
Short % of Float	3.13%
Short Ratio (days to cover)	2.29

Income Statement

In the last 12 months, FibroGen had revenue of $180.02 million and -$121.79 million in losses. Loss per share was -$1.22.

Revenue	180.02M
Gross Profit	-15.16M
Operating Income	-119.04M
Pretax Income	-168.39M
Net Income	-121.79M
EBITDA	-114.82M
EBIT	-119.04M
Loss Per Share	-$1.22

Balance Sheet

The company has $131.00 million in cash and $92.98 million in debt, giving a net cash position of $38.03 million or $0.38 per share.

Cash & Cash Equivalents	131.00M
Total Debt	92.98M
Net Cash	38.03M
Net Cash Per Share	$0.38
Equity (Book Value)	-201.70M
Book Value Per Share	-2.42
Working Capital	54.00M

Cash Flow

In the last 12 months, operating cash flow was -$125.85 million and capital expenditures -$376,000, giving a free cash flow of -$126.23 million.

Operating Cash Flow	-125.85M
Capital Expenditures	-376,000
Free Cash Flow	-126.23M
FCF Per Share	-$1.25

Margins

Gross margin is -8.42%, with operating and profit margins of -66.13% and -67.66%.

Gross Margin	-8.42%
Operating Margin	-66.13%
Pretax Margin	-67.73%
Profit Margin	-67.66%
EBITDA Margin	-63.78%
EBIT Margin	-66.13%
FCF Margin	n/a

Dividends & Yields

FibroGen does not appear to pay any dividends at this time.

Dividend Per Share	n/a
Dividend Yield	n/a
Dividend Growth (YoY)	n/a
Years of Dividend Growth	n/a
Payout Ratio	n/a
Buyback Yield	-3.41%
Shareholder Yield	-3.41%
Earnings Yield	-171.22%
FCF Yield	-177.45%

Analyst Forecast

The average price target for FibroGen is $10.00, which is 1,316.63% higher than the current price. The consensus rating is "Strong Buy".

Price Target	$10.00
Price Target Difference	1,316.63%
Analyst Consensus	Strong Buy
Analyst Count	1
Revenue Growth Forecast (5Y)	16.89%
EPS Growth Forecast (5Y)	n/a

Stock Splits

This stock does not have any record of stock splits.

Last Split Date	n/a
Split Type	n/a
Split Ratio	n/a

Scores

FibroGen has an Altman Z-Score of -10.53 and a Piotroski F-Score of 2. A Z-score under 3 suggests an increased risk of bankruptcy.

Altman Z-Score	-10.53
Piotroski F-Score	2